Hoth Therapeutics, Inc. (NASDAQ: HOTH), a US-based biopharmaceutical company, announced on Wednesday that it has chosen three of its US clinical sites for its Phase 2a clinical trial to treat rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

The first three clinical sites for the study are in St Louis, Missouri; Miami, Florida and Houston, Texas.

EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. The phase 2a dose ranging study, as well as a proposed follow-up phase 2b safety and efficacy dose extension study, will be conducted in cancer patients receiving EGFR inhibitor therapy.